Soy isoflavones are naturally occurring phytochemicals, which are biotransformed into functional derivatives through oxidative and reductive metabolic pathways of diverse microorganisms. Such representative derivatives, ortho-dihydroxyisoflavones (ODIs) and equols, have attracted great attention for their versatile health benefits since they were found from soybean fermented foods and human intestinal fluids. Recently, scientists in food technology, nutrition and microbiology began to understand their correct biosynthetic pathways and nutraceutical values, and have attempted to produce the valuable bioactive compounds using microbial fermentation and whole-cell/enzyme-based biotransformation. Furthermore, artificial design of microbial catalysts and/or protein engineering of oxidoreductases were also conducted to enhance production efficiency and regioselectivity of products. This minireview summarizes and introduces the past year's studies and recent advances in notable production of ODIs and equols, and provides information on available microbial species and their catalytic performance with perspectives on industrial application.
INTRODUCTION
Soybean is a representative legume containing fair amount of isoflavones ranging from 0.1 to 0.3% of its total weight, which are mainly consisted of daidzein, genistein and glycitein predominantly as malonyl-, acetyl-and β-glucoside conjugates (Wang and Murphy 1994) . Unlike flavones, isoflavones are phytoestrogens, and their derivatives sometimes become selective estrogen receptor (ER) modulators due to their preferential binding properties to human ERs and activator function, especially for ERβ (Kuiper et al. 1998; Setchell 2001; Hwang et al. 2006) . The estrogenic characters of isoflavones are practically associated with relieving post-menopausal symptoms, so that more than 75 mg/d dietary isoflavone (or 15 mg/d genistein) intake has been nutraceutically recommended for alleviating osteoporosis, hot-flash and low-density lipoprotein cholesterol level (Uesugi, Fukui and Yamori 2002; Williamson-Hughes et al. 2006; Wei et al. 2012) . Recently, it was revealed that the biological estrogenic effects of isoflavone could not be simply explained by the intake of isoflavone itself, but its metabolism of host intestinal microflora plays an important role for the individual effects (Setchell, Brown and Lydeking-Olsen 2002) . Especially, equol, a reduced metabolite of daidzein, was clinically verified for various biological activities on menopausal disorders, antibreast/prostate cancer, anti-oxidative and anti-skin aging with significant higher efficiency, compared to its isoflavone origin (Setchell et al. 2005; Jackson, Greiwe and Schwen 2011; Itsumi et al. 2016; Lephart 2016) .
Those kinds of enhancement in the biological activities of structurally derivatized isoflavone can be also found in the products of traditional soy fermented foods. Fermented soy pastes such as Doenjang (from Korea), Miso (from Japan), Douchi (from China) and Tempeh (from Indonesia) contain a variety of isoflavone derivatives subjected to oxidoreductions, but their hydroxylation modifications were the best studied (György, Murata and Ikehata 1964; Hirota et al. 2004; Chen et al. 2005; Park et al. 2008 ). The hydroxylation is mainly performed by several microorganisms during fermentation, and the hydroxylated isoflavones can function as beneficial components for human health with superior bioactivity to original isoflavones without fermentation. For example, ortho-dihydroxyisoflavones (ODIs) in the soy foods were reported to show anti-inflammatory, anti-cancer and anti-oxidant activities through various biological mechanisms . Because they share the catechol functional group in the polyphenol backbone, their radical-scavenging efficacy is common property with some variations according to the position of hydroxyl groups on the aromatic rings (Park et al. 2008 ). Moreover, 6-ODI and 8-ODI have been validated to show preventive effects on adipogenesis (anti-diabetic effect) and atopic dermatitis symptoms (skin anti-inflammatory effect), respectively . In a recent study, 8-ODI has been also validated to show preventive effect on atherosclerosis via attenuating adhesion of THP-1 monocytes to human vein endothelial cells (Lee et al. 2018a) .
To utilize the benefits of isoflavone derivatives, sufficient production method should be secured with acceptable costs and available large quantity. However, most isoflavone derivatives have restrictions in commercialization due to lack of natural sources, efficient biocatalysts and production/purification methods. In this review, industrially applicable microbial hosts and biocatalytic systems for the production of isoflavone derivatives are systematically presented with recent information on their preparation methods, titers and productivity. Among variety of isoflavone derivatives, especially modified products with hydroxylation (ODIs) and multiple reductions (equol) are intensively reviewed, which differs from the previous reviews (Chang 2014; Cao et al. 2015; Pandey et al. 2016) .
ORTHO-DIHYDROXYISOFLAVONES PRODUCTION USING ISOLATED STRAINS
Most hydroxylation products of isoflavone have ortho-dihydroxy functional groups at 3 /4 , 6/7 or 7/8 positions of its A and B rings' backbone ( Fig. 1) . Then, isolation, bioactivity and production of ODIs were thoroughly reviewed by Chang (2014) . Although the review compared several microbial productions of ODIs, newly reported preparation methods since then are systematically summarized in this review (Table 1) . Historically, isolation of ODIs was first achieved by biotransformation using fungal and microbial species as living catalysts (Umezawa et al. 1975) . Especially, Aspergillus and Streptomyces isolated from traditional soybean fermented foods are known for potent target species for ODI production. For example, Aspergillus saitoi is one of the first isolated fermentation strains verified to produce 8-orthohydroxydaidzein (OHD) and 8-ortho-hydroxygenistein (OHG) (Esaki et al. 1998) . The Japanese researchers observed that the hydroxylation at the 8-position of A ring of isoflavones was induced at the stage of sporulation during solid and liquid-phase 
Nocardia farcinica 
CYP57B3-bmCPR soybean fermentations (Esaki et al. 1999b) . Another strain A. oryzae was then found to produce 6-OHD in addition to 8-OHD and 8-OHG (Esaki et al. 1999a) . Since the potent Aspergillus strains were isolated, regiospecific production of 8-hydroxyisoflavones has been extensively investigated using A. oryzae species. selected A. oryzae KACC 40247 from 60 fungal strains, and the strain could transform isoflavones in soybean extract into 8-hydroxydaidzein with strict regioselectivity and fine titer (i.e. 62 mg/L), which was further maximized to 95 mg/L and 3.2 mg/L/h with the addition of daidzein, and 160 mg/L and 4.4 mg/L/h with the addition of daidzin, respectively under optimal conditions. Wu et al. (2015) and Wu and Chang (2016) also reported satisfactory productions of 8-OHD and 8-OHG, i.e. 52 and 83 mg/L, respectively using A. oryzae BCRC32288 strain. It is noteworthy that these fungal strains are compatible with large-scale fermentation (3-7 L), which makes these strains highly promising candidates for industrial application.
Streptomyces, another class of isoflavone hydroxylating microorganisms, has been also recognized as a potent ODIproducing strain. Komiyama et al. (1989) observed diverse hydroxylated isoflavone products from fermentation broth of Streptomyces sp. OH-1049, which included 3 -OHD and 8-OHD . Afterward, Roh et al. (2009b) screened diverse microbial strains including Actinomyces, Bacillus spp. and several fungal strains for their ability to hydroxylate daidzein and genistein, then Streptomyces avermitilis MA-4680 represented efficient conversion rate with regioselective production of 3 -OHD (37.5 mg/L) and 3 -OHG (22.9 mg/L).
Other microbial strains including Rhizopus and Nocardia were also reported to have ability to convert isoflavone to corresponding ortho-hydroxylated products (György, Murata and Ikehata 1964; Ikehata, Wakaizumi and Murata 1968; Maatooq and Rosazza 2005; Choi et al. 2009 ). However, their catalytic efficiency was far lower than the abovementioned Aspergillus and Streptomyces strains. Therefore, those microbial strains with naturally high ability to hydroxylate isoflavones are recommended for fermentation or whole-cell biotransformation process for practical food or pharmaceutical applications.
ORTHO-DIHYDROXYISOFLAVONES PRODUCTION USING RECOMBINANT STRAINS AND ENZYMES
Afterward, scientists took a different route to prepare target ODIs using recombinant cloned monooxygenases into the abovementioned strains or Escherichia coli. Their works were motivated by low ODI productivity, titer and regioselectivity of natural microorganisms. Another reason is consecutive structural modifications of generated ODIs through secondary metabolic pathways of ODI-producing strains. The ODIs were observed to undergo further O-methylation or O-glycosylation reactions, thereby resulting in low productivity (Choi et al. 2009 ). In order to overcome those limitations, mainly cytochrome P450s, flavin-dependent monooxygenase and recently tyrosinase have been adopted for efficient isoflavone hydroxylation in the recombinant strains. Among them, cytochrome P450s are the most well investigated biocatalyst for ODI synthesis ( Fig. 2A) . Cytochrome P450 (CYP) activates a molecular oxygen in the heme complex coordinated by a backbone cysteine. The hemeoxygen complex is reduced by electrons coupled with NAD(P)H oxidation, which generates a highly reactive Fe = O (IV) complex named 'Compound I' that finally hydroxylates isoflavone into ODI with specific regioselectivity (Shaik et al. 2005) . The P450 study for ODI production was conducted in five major directions of P450 identification, redox protein coupling, NAD(P)H cofactor supply, P450 engineering and host development, which were mainly performed by our group and Te-Sheng Chang's group. At first, our group focused on screening of functional bacterial species with isoflavone hydroxylation activity, then could find out two microbial species, S. avermitilis MA4680 and Nocardia farcinica IFM10152, which predominantly perform B-ring and A-ring ortho-specific hydroxylations, respectively (Choi et al. 2009; Roh et al. 2009b ). These two bacterial strains showed outstanding isoflavone hydroxylation activity compared to previously reported microbial genera including Arthrobacter and Micrococcus (Klus and Barz 1995) . Then, their hydroxylation activity was revealed mainly due to endogenous cytochrome P450 monooxygenases: CYP105D7/CYP107Y1 from S. avermitilis MA4680 and Nfa12130/Nfa33880 from N. farcinica IFM10152, respectively (Choi et al. 2009; Pandey et al. 2010 Pandey et al. , 2011 . In addition, when the cytochrome P450s were overexpressed with nonnative promoters, the microbial catalysts produced significantly higher titer of ODIs (37.5 mg/L of 3 -OHD (Pandey et al. 2010) , 7.2 mg/L of 3 -OHG (Pandey et al. 2011) ), while wild-type strain only produced 9.0 and 2.3 mg/L of 3 -OHD and 3 -OHG, respectively. Meanwhile, the catalytic efficiency of the cytochrome P450s could be improved by heterologous overexpression in Streptomyces host, co-expression with the innate redox partners or artificial fusion with redox protein for self-sufficient and highly coupled electron supply (Choi et al. 2012b (Choi et al. , 2014 Pandey et al. 2014a) . On the other hand, Te-Sheng Chang et al. thoroughly investigated fungal cytochrome P450s and their heterologous expression in recombinant yeast strains which were recognized as valuable microbial cell factories for functional expression of membrane-anchored eukaryotic cytochrome P450s. At first, the researchers selected a cytochrome P450, CYP57B3 previously isolated from A. oryzae, which played a major catalytic role in forming ortho-hydroxylation of genistein (Nazir, Ichinose and Wariishi 2011) . When the CYP57B3 was artificially fused with the reductase domain of CYP102A1 (BM3) from Bacillus megaterium, the recombinant Pichia pastoris harboring the chimeric P450 showed 9.1 mg/L of 6-OHD, which is the highest production level reported ever (Chang, Chao and Chen 2013) . The same group also performed several other constructions of chimeric CYPCPRs (cytochrome P450 reductases) for preparation of versatile ODIs. Then, CYP57B3-sCPR (CPR from Saccharomyces cerevisiae) in P. pastoris was verified for efficient production of 3 -OHG with 3.5 mg/L titer, which was further improved to 23.0 mg/L by a following study in which the recombinant yeast was subjected to laboratory evolution during periodic hydrogen peroxide shocking (Ding et al. 2015; Wang et al. 2016) . Meanwhile, another chimeric enzyme was constructed with a fusion of transmembrane domain (from CYP57B3), CYP105D7 (from S. avermitilis MA4680) and CPR (from S. cerevisiae), then recombinant P. pastoris harboring the chimera enzyme achieved 7.5 and 15.0 mg/L titers for 6-OHD and 3 -OHG in 5 L scale fermentation, respectively ). According to these pioneering studies performed by our group and Te-Sheng Chang's group, Streptomyces and Pichia strains were potent hosts for ODI production, since the strains preserve high redox potentials in the cell during biotransformation, tolerate organic solvents and large-scale fermentation, and act as a good platform for heterologous expression of recombinant (membrane) proteins (Choi et al. 2014; Schwarzhans et al. 2017) .
Even though the abovementioned investigations enabled microbial production of ODIs in semi-preparative scale, the low Figure 2 . Reaction schemes for 3 -ODI biosynthesis from daidzein in the microbial catalysts-mediated biotransformation system using (A) cytochrome P450, and (B) tyrosinase as major isoflavone hydroxylase enzymes. The molecular oxygen activating prosthetic groups (i.e. heme for P450 and di-coppor complex for tyrosinase) in the respective enzymes were simplified along the oxidation states of the prosthetic groups and isoflavone. Each abbreviation indicates as follows: Cyt P450: cytochrome P450, CPR: cytochrome P450 reductase, S: substrate, P: product, NAD(P)H or NAD(P) + : nicotinamide adenine dinucleotide (phosphate) reduced or oxidized forms, Ty:
tyrosinase, R: omitted backbone of isoflavone. The schemes are modified versions of the previously reported (Choi et al. 2014; Lee et al. 2016b) .
catalytic efficiency of ODI monooxygenase, mainly cytochrome P450, is far below the requirements of industry for sufficient high productivity and titer of valuable ODIs. Motivated by such problems, researchers tried to enhance the enzyme specific activity by random or directed evolution. CYP102D1, a single self-sufficient P450 identified as long-chain fatty acid hydroxylase from S. avermitilis MA4680, was a target for protein engineering, and F96V/M246I mutations increased 15-fold in catalytic efficiency for daidzein to ODI conversion (Choi et al. 2012a) . The mutant became a template for second-generation saturation mutagenesis, then additional A273S/T277R mutations redirected its regioselectivity over the 3 /6-position by 3-fold with 23-fold improved hydroxylation activity (ODIs, 48.4 mg/L) (Choi, Yang and Kim 2015) . Another well-known selfsufficient bacterial P450, CYP102A1 (BM3) from B. megaterium, was also virtually screened to obtain isoflavone hydroxylation activity, which finally generated several improved variants with mutations at substrate access channel entrance and substrate binding sites. CYP102A1 F87A was able to produce ODI and additional mutation of Y51A changed regioselectivity favorable C3 over C6 position (Ko et al. 2015) . For CYP57B3, a potent fungal P450 for ODI hydroxylation, a variant with single substitution of V138I was recently screened for 14-fold higher production of 3 -OHG (Hatakeyama, Kitaoka and Ichinose 2017) . Even though these extensive studies offer a cytochrome P450-based biotransformation platform for regioselective production of ODIs, their titer and productivity were still insufficient for the industrial application. The major drawback of the biotransformation is chronic disadvantages of cytochrome P450: low catalytic activity, stability, low electron coupling efficiency and cofactor dependency (Urlacher and Girhard 2012) . The habitual obstacle was partially overcome by exploiting a non-heme flavin-dependent monooxygenase, Sam5 from Saccharothrix espanaensis as an efficient regioselective biocatalyst for 3 -hydroxydaidzein production (75 mg/L in titer, 3.1 mg/L/h in productivity) (Lee, Kim and Ahn 2014) . The researchers adopted E. coli whole-cell biotransformation system because the hydroxylase is also highly dependent on the available cellular reducing cofactor, i.e. NAD(P)H. Next, the ODI production underwent dramatic breakthrough by introduction of tyrosinase-catalyzed reaction system in recent years. At first, tyrosinase seemed not to be a good catalyst for the ortho-hydroxylation, since its catecholase activity oxidizes catechol compounds to quinones and finally melanin complex, preventing selective ODI production. In a previous microbial production, a tyrosinase (MelC2) from S. avermitilis MA4680, therefore, was a deletion target to increase ODI yield in cytochrome P450-mediating hydroxylation system (Pandey et al. 2014a ). On the other hand, monophenolase activity of tyrosinase was successfully exploited to give ortho-hydroxylation of aromatic substrates by supplementation with additional reducing agents (Lee et al. 2015) . In this study, additions of catechol, NADH and ascorbic acid sacrificially inhibited melanin formation, resulting efficient bioconversion of trans-resveratrol into piceatannol (3 -hydroxy-trans-resveratrol). In next, the same tyrosinase was used to convert daidzein to 3 -OHD in free-reducing cofactor (i.e. NAD(P)H) manner. However, another tyrosinase with different microbial origin (B. megaterium) was superior for the production of 3 -ODI (Lee et al. 2016b) . In this study, borate chelation at basic pH was strategically adopted to inhibit diphenolic 3 -ODI oxidation to quinone or melanin (Fig. 2B) . The reaction system also increased 3 -OHD and 3 -OHG (orobol) with remarkable titers 1.35 and 0.27 g/L from daidzein and genistein, respectively (Lee et al. 2016b) . The productivities and titers of ODIs highly exceeded the previous levels achieved by cytochrome P450s. The dramatic breakthrough seems due to no reductive cofactor requirement and higher enzymatic activity, i.e. more than 10-100 fold. Similarly, Te-Sheng Chang group adopted the same catalyst and chelating system to prepare 3 -ODI glycosides with fine titers, suggesting the microbial tyrosinase has broad substrate specificity (Chiang, Wang and Chang 2016) . However, the tyrosinase was abandoned to produce different regiomeric ODIs rather than 3 -ODI. Its limited regioselectivity might be caused by inhibitory mechanism of the ODIs against the tyrosinase . In fact, 6-ODI and 8-ODI are potent competitive and suicide tyrosinase inhibitors, respectively (Chang, Ding and Lin 2005; Chang 2007 ). In addition, A-ring of isoflavone is more reluctant to hydroxylation than its B-ring owing to its structural bulkiness and higher pK a value of the phenolic group at C7 over C4 . Therefore, the preparation of ODIs with specific hydroxylation at A-ring is recommended to use other enzymes such as cytochrome P450 rather than tyrosinase.
PRODUCTION OF A REDUCTIVE METABOLITE OF ISOFLAVONE: EQUOL
Equol, a reduced metabolite of daidzein, belongs to isoflavan class that lacks the ketone group on isoflavone C-ring. Equol is abundantly found in Asian soybean fermented products such as stinky tofu (Jou et al. 2013 ); however, its major origin was known as a metabolic product by gut microflora (Tsangalis et al. 2005; Wang et al. 2005 Wang et al. , 2007 . Therefore, plant isoflavones digested by mammalian hosts are actually transformed into equol and its derivatives by host commensal gut bacteria, then equol is finally absorbed into the hosts with moderate estrogenic activity. Because of most isoflavones are β-conjugated with glucose at 7-O of A ring, hydrolysis of 7-O-β-glycosides using glucosidase is required prior to its metabolic conversion into equol Yuan, Wang and Liu 2007) . Some of intestinal bacteria, mainly Bifidobacteria and Lactobacillus are predominantly responsible for the deglycosylation, producing isoflavone aglycones (Wei, Chen and Chen 2007; Raimondi et al. 2009 ). The microorganisms bear low and high glycoside loads, and among them, Lactococcus lactis ESI515 showed maximal conversion (>90%) for 5 mM of daidzin and genistin into respective aglycones and dihydroisoflavones in a recent study (Gaya, Peirotén and Landete 2017) .
Over the past decade, equol-producing bacteria have been thoroughly isolated and classified, and the bacterial species comprise a variety class of microorganisms including Coriobacteriaceae (i.e. Slackia, Eggerthella, Adlercreutzia), Lactococcus, Lactobacillus, Bifidobacterium, Pediococcus genus, etc. (Table 2) . Most of the equol-producing bacteria are strictly anaerobes with one recent exceptional study: Pediococcus, Lactobacillus sp. (Kwon et al. 2018) . Equol-producing capacity is quite different among the equol-producing bacteria, even though they are speculated to share the same enzymatic pathway. Microbial species, which show relatively higher equol production titers and productivities, predominantly belong to Coriobacteriaceae family in general, while other equol-producing bacteria including Bifidobacterium and Eubacterium tends to show poor titer or productivity (Table 2 , Tsangalis et al. 2002; Yu, Yao and Zhu 2008) . This kind of tendency could be also found in the previous patents. A patent claimed a lactic acid bacterium producing equol, which is now classified as Lactococcus garvieae strain (Uchiyama, Ueno and Suzuki 2006; Shimada et al. 2010) . The inventors could achieve 57 mg/L of anaerobic equol production during 96 h of soymilk fermentation. On the other hand, another Japanese patent (JP5631862B2) claimed that the fermentation exploiting Slackia sp. YIT 11861 converted 100 mg/L of daidzein into (S)-equol with 94% conversion yield in 24 h, which is quite superior to the previous fermentation using Lactococcus strain that showed no conversion of 10 mg/L daidzein in 24 h (Tsuji et al. 2013) . The same bacteria also tolerated 10 L anaerobic fermentation to give 2.4 g of equol from 2.5 g of daidzein, which made the Slackia strain more acceptable for industrial application. In addition, Coriobacterium, mainly Slackia species, is the unique microorganism producing 5-hydroxy-equol from genistein, whereas other equol-producing bacteria do not (Matthies et al. 2008; Matthies, Blaut and Braune 2009; Xie et al. 2015) . It is very likely that Slackia has better potency and broad substrate specificity in the isoflavone reduction.
Some recent studies identified a gene cluster responsible for equol-producing activity of the bacteria. The gene cluster encodes 3 to 8 homologous open-reading frames varying among microbial species. However, only four genes encoding daidzein reductase (DZNR), dihydrodaidzein racemase (DDRC), dihydrodaidzein reductase (DHDR) and tetrahydroaidzein reductase (THDR) are identified as key factors in the reductive isoflavone pathway (Tsuji et al. 2012; Schroder et al. 2013; Kawada et al. 2016) . Isoflavone reduction is firstly achieved by DZNR which gives a saturated CC single bond between C2 and C3 of daidzein or genistein to produce dihydrodaidzein (DHD) or dihydrogenistein (DHG), respectively (Shimada et al. 2010; Schroder et al. 2013) . The tautomerization at C4 ketone and DDRC easily isomerizes and produces racemic mixture of DHD (Park, Kim and Han 2011; Shimada et al. 2012) . Both DHD isomers are reduced at C4 ketone to alcohol by DHDR generating (3S,4R)-transtetrahydrodaidzein (THD) and (3R,4R)-cis-THD, respectively. Finally, only (3S,4R)-trans-THD is metabolized into (3S)-equol by THDR (Shimada et al. 2011) . Because the metabolism of daidzein into equol is dependent on three reductases and an isomerase, the metabolic process is highly dependent on intracellular reducing power. In practice, DZNR and DHDR consume NADPH as an electron donor to reduce isoflavonoid substrates, whereas DDRC and THDR are verified as cofactor-independent enzymes (Shimada et al. 2011 (Shimada et al. , 2012 . However, low catalytic activity of THDR in in vitro assay and thermodynamically speculated existence of extra reducing power strongly insist that unknown reduction mechanism is still remained to be seen (Schroder et al. 2013) . Only putative catalytic mechanisms including a route via radical-intermediate or dismutase activity (sacrificing one THD to DHD for production of one equol) were suggested without experimental confirmation Kawada et al. 2016) . The identification of equol-producing enzymes from gut bacteria opened up new ways to construct artificial equol-producing bacteria, which could be used as efficient microbial cell factories for large-scale equol production. This research theme was solely conducted by our group. We constructed a recombinant E. coli strain harboring the four abovementioned genes originated from Slackia isoflavoniconvertens DSM22006 (Lee et al. 2016a) . The recombinant bacteria were used as whole-cell catalyst and efficiently converted daidzein and genistein into equol (206 mg/L) and 5-hydroxy-equol (230 mg/L), respectively, with remarkable productivities (51.5 and 38.0 mg/L/h, respectively) (Lee et al. 2017) . Supplemented with hydrophilic polymers for aqueous solubilization of isoflavone, (S)-equol titer was maximally increased up to 1.2 g/L (Lee et al. 2018b) . The recombinant strain also takes advantage of aerobic manipulation, a favorable fermentation process for industrial-scale production. Interestingly, the recombinant strain converted genistein into 5-hydroxy-dehydroequol, a novel isoflavene firstly identified in this study. The high production rate of the artificial equol-producing strain, therefore, could offer a catalytic platform to produce versatile bioactive equol derivatives such as 6-methoxy-equol, because several studies demonstrated that 6-methoxy-equol could be also formed from glycitein (a third abundant isoflavone in soybean) by certain gut bacteria (Simons et al. 2005) . Recently, Pediococcus and Lactobacillus strains were isolated from human feces and they were also shown to produce equol from daidzin, daidzein and DHD in aerobic fermentation (Kwon et al. 2018) . This is the first observation of aerobic production of equol by naturally isolated gut bacteria with high efficiency. Such bacteria are promising candidates for future development of industrial aerobic fermentation process, which would lead low-cost equol production and its successful commercialization, since food industry still mainly requires non-GMO (genetically modified organism) products.
EQUOL ANALOGs
Since equol is a very well-characterized phytoestrogen and a lot of patents claim its compositions in products, applications and preparations, researchers in industries pay attention toward other equol analogs giving similar or even better biological efficacies to evade the existing claims. The analogs include glycosylation, hydroxylation and other chemical modifications of equol. Glycosylated equol derivative is one of the most wellknown industrialized product. Hayashibara Co., Ltd. (Japan) invented a novel application of equol glycosides as an effective whitening cosmetic ingredient (Nakano et al. 2010; Miyake et al. 2014) . The equol glycosides have α-conjugated D-glucose to the OH groups at either C4 or C7 of (S)-equol or (R)-equol. The inventors utilized sequential batch reactions of cyclomaltodextrin glucanotransferase (CGTase) and glucoamylase for preparing 4'-O-α-D-glycosyl-equol and 7-O-α-D-glycosyl-equol from 1 g of equol with approximate 4 and 5% purification yields, respectively (Nakano et al. 2010) . Synthesis of β-Glycosyl-equol has not been reported yet, but possible glycosyltransferase candidates would be YjiC, GmUGTs and OleD, which have 4 or 7-O-glucosylation activity toward isoflavones (Zhou et al. 2013; Pandey et al. 2014; Funaki et al. 2015) . It is also reported that injested equol could be conjugated with sulfate and glucuronide groups in plasma and urine (Schwen, Nguyen and Jackson 2012) .
Hydroxylation of equol has also been suggested in vitro. Indeed, Rufer et al. detected hydroxy-equols in the equol-fed reaction of human liver microsomes. The major hydroxylated products involve 3 -hydroxy-equol, 6-hydroxy-equol and 8-hydroxyequol (Rufer 2005) . Such modifications are likely to be catalyzed by mammalian cytochrome P450s, but no enzymes were verified yet. Only (-)-5-hydroxy-equol is naturally synthesized from genistein by intestinal bacteria with relatively lower production efficiency than daidzein to equol conversion, and binds to ERs with lower affinity than equol (Matthies et al. 2012; Lee et al. 2017) . Interestingly, 5-hydroxy-equol exhibits the highest antioxidant activity among other isoflavone derivatives including equol, 4-hydroxy-equol, daidzein and genistein (Arora, Nair and Strasburg 1998) . However, most of hydroxy-equols lack their identified biological activities which are remained to be seen.
A COUSIN OF EQUOL: O-DESMETHYLANGOLENSIN
Another noteworthy reductive isoflavone derivative is Odesmethylangolensin (O-DMA), a cousin isoflavonoid of equol with C-O cleavage in C-ring of isoflavonoid backbone. O-DMA is also known as a phytoestrogen, but its estrogenic potency is lower than that of daidzein and equol (Frankenfeld 2011) . Particular intestinal bacteria could convert daidzein or genistein into O-DMA or 6'-hydroxy-O-DMA, respectively (Hur et al. 2002; Schoefer et al. 2002) . The microbial species include Clostridium species, Enterococcus faecium and Eubateriumm ramulus ( Table 2) . Biosynthesis of O-DMA shares a part of the (S)-equol metabolic pathway: daidzein to DHD, then DHD undergoes C-O bond cleavage in C-ring, and the intermediate is transformed into O-DMA (Hur et al. 2002) . Biologically synthesized O-DMA mainly exists as R-enantiomer derived from its direct precursor, S-DHD (Gardana, Canzi and Simonetti 2014; Kim and Han 2014; Niwa et al. 2015) . Even though several O-DMA-producing intestinal bacteria have been isolated, the responsible enzyme for the conversion has not been identified yet. Recently, a representative strain producing O-DMA, Clostridium sp. SY8519, was identified by a complete whole-genome sequencing (Yokoyama et al. 2011) , but the researchers could not identify genetic relationship between possible open reading frames and daidzein metabolism. In general, O-DMA-producing bacteria are also able to metabolize genistein into 6'-hydroxy-O-DMA that is finally converted into 2-(4-hydroxy-phenyl) propionic acid (2-HPPA) (Niwa et al. 2015) . In a recent study, a potent O-DMA-producing intestinal bacteria, E. faecium INIA P553, was introduced with the highest O-DMA and 6 -hydroxy-O-DMA production titers (i.e. 960 and 373 mg/L, respectively) reported ever (Gaya et al. 2018) . Like equol-producing bacteria, O-DMA-producing bacteria also require anaerobic growth condition for O-DMA production. But Dr. Wang and her colleagues developed oxygen-tolerant strains via incremental laboratory evolution to overcome the strict anaerobic traits of natural O-DMA-producing bacteria, which enabled anaerobic fermentation and O-DMA production with better economic handling (Li et al. 2015) .
CONCLUSION
ODIs and equol are bioactive isoflavone derivatives having natural origins from soybean. Their benefits for human health and alleviating efficacy for various adult and lifestyle diseases are well known, getting more attention. However, poor commercial availability of the bioactive compounds prevented their general use. Over a recent decade, isolation of promising candidate bacteria, and their improvement using laboratory evolution or genetic manipulation paved the road toward quantitative preparation and commercialization of the isoflavone derivatives. In addition, the enhancement of fermentation technique and reaction process highly associated with microbial catalysts dramatically improved the production titer and productivity to acceptable levels for broad fields of industry where the products could be used as food additives, cosmetic ingredients and even pharmaceuticals. Despite the successful progress in biotechnological developments, there are still several problems to be overcome in future. The problems involve low isoflavone solubility, legal regulation against using genetically engineered microorganisms and still high production costs. Further technological and nutritional investigations and clinical trials for the application of isoflavone derivatives will provide great benefits to human health and daily life in future. 
